LAVA Therapeutics First Quarter 2024 Earnings: US$0.021 loss per share (vs US$0.53 loss in 1Q 2023)
LAVA Therapeutics NV LVTX | 1.74 | Delist |
LAVA Therapeutics (NASDAQ:LVTX) First Quarter 2024 Results
Key Financial Results
- Revenue: US$6.99m (up 471% from 1Q 2023).
- Net loss: US$553.0k (loss narrowed by 96% from 1Q 2023).
- US$0.021 loss per share (improved from US$0.53 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
LAVA Therapeutics Earnings Insights
Looking ahead, revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 6.4% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 4 warning signs for LAVA Therapeutics you should be aware of, and 2 of them are significant.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.